At present, for the majority of chronic hepatitis B patients, the correct choice is to formulate a standardized individualized antiviral treatment plan under the guidance of specialists and adhere to the antiviral treatment in order to maximize the suppression of viral replication and block the occurrence of liver cirrhosis or hepatocellular carcinoma. Do not blindly wait for the therapeutic hepatitis B vaccine to be marketed and delay treatment. Even if the therapeutic hepatitis B vaccine is successfully developed and marketed, it cannot replace antiviral drugs, and one vaccine should not be expected to solve all the problems of HBV infection. It is better to combine with antiviral drugs, “two-pronged approach” to achieve long-term suppression or elimination of hepatitis B virus.